Joint fluid therapy has new directions for use

March 20, 2006

The FDA has approved new labeling for Supartz, an injectable form of hyaluronic acid that is used for the treatment of pain from osteoarthritis of the knee. New directions for use now allow physicians to choose as few as three intra-articular injections for a course of therapy, instead of the previously approved five weekly injections.

Joint fluid therapy has new directions for use

The FDA has approved new labeling for Supartz, an injectable form of hyaluronic acid that is used for the treatment of pain from osteoarthritis of the knee. New directions for use now allow physicians to choose as few as three intra-articular injections for a course of therapy, instead of the previously approved five weekly injections. Supartz was originally approved by the FDA in 2001 and, according to manufacturer Smith & Nephew, is intended for patients who have failed to adequately respond to conservative, nonpharmacologic therapy and simple analgesics, such as acetaminophen.

To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.